Xcout Intel
Scilex Holding Co
Scilex Holding Company operates as a biopharmaceutical firm primarily engaged in creating and distributing non-opioid treatments for individuals suffering from acute and chronic pain conditions. Its flagship product, ZTlido 1.8%, is a prescription-only topical lidocaine formulation designed to alleviate neuropathic pain, specifically that associated with post-herpetic neuralgia, a type of nerve pain occurring after a shingles infection. The company's development pipeline also features SP-102, known as SEMDEXA, a viscous corticosteroid gel administered via epidural injections. This candidate is currently in Phase 3 clinical trials, targeting lumbosacral radicular pain. Another investigational drug, SP-103, aims to treat low back pain and is progressing through Phase 2 clinical trials. Additionally, SP-104, an innovative low-dose, delayed-release naltrexone hydrochloride formulation, is in Phase 1 clinical development for managing fibromyalgia. Scilex Holding Company is headquartered in Palo Alto, California, and functions as a subsidiary of Sorrento Therapeutics, Inc.
Subscribe to see Scilex Holding Co’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Scilex Holding Co at a glance
Scilex Holding Co is a pharmaceuticals company headquartered in Palo Alto, United States. It has raised at least $104.6M across the 2 funding rounds on record. Its most recent funding round raised $2.7M in September 2025. Xcout tracks 23 named people at Scilex Holding Co, including Henry H. Ji (Chief Executive Officer, President & Executive Chairman).
Scilex Holding Co leadership
- Henry H. JiChief Executive Officer, President & Executive Chairman
- Henry JiChief Executive Officer and President
- Stephen MaSenior Vice President, Chief Financial Officer, Chief Operating Officer, Corporate Secretary & Director
- Suketu D. DesaiInterim Chief Technical Officer & Senior Vice President
- Dmitri V. LissinSenior Vice President of Clinical Development and Medical Affairs & Interim Chief Medical Officer
- Suresh K. KhemaniSenior Vice President, Chief Commercial Officer & GM of Scilex Pharma
17 more named people on record for Scilex Holding Co, with roles, board committees and tenure — see the full roster →
Scilex Holding Co funding rounds
At least $104.6M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $2.7M | — | |
| SEC Form D filing | $101.9M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Scilex Holding Co competitors
A few of Scilex Holding Co's closest competitors — see the full list of competitors and alternatives →
Semnur Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company developing non-opioid therapies for pain. Its lead candidate, SP-102 (depot dexamethasone sodium phosphate), was developed for the treatment of sciatica and other radicular pain conditions.
Pacira BioSciences, Inc. is a pharmaceutical manufacturing company headquartered in Parsippany, New Jersey, with operations in locations such as Brisbane, California. The company is dedicated to transforming pain management by delivering innovative, non-opioid therapies.
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
Nutra Pharma Corp. (NPHC) operates as a biopharmaceutical firm specializing in obtaining, licensing, and bringing to market a variety of pharmaceutical products, cutting-edge technologies, and both homeopathic and ethical medications. The company primarily targets the U.S. market, focusing its efforts on managing conditions such as pain, neurological ailments, cancer, autoimmune diseases, and infectious diseases. Its current commercial offerings include: Nyloxin and Nyloxin Extra Strength: These products are distributed as an oral spray for alleviating lower back pain, migraines, neck and shoulder discomfort, cramps, and neuropathic pain, and as a topical gel to relieve joint pain, arthritis, and repetitive stress injuries. Pet Pain-Away: An over-the-counter (OTC) homeopathic, non-narcotic, and non-addictive solution for chronic pain in household pets. Luxury Feet: An OTC pain reliever and anti-inflammatory designed to ease foot pain or discomfort specifically caused by high heels and stilettos. Nyloxin Military Strength: A specialized formulation for pain relief aimed at the United States Military and Veteran's Administration. Equine Pain-Away: An OTC topical pain management product for horses. Beyond its existing portfolio, Nutra Pharma Corp. is also advancing several pipeline candidates: RPI-78M: In development to treat neurological conditions such as multiple sclerosis, adrenomyeloneuropathy, and amyotrophic lateral sclerosis, alongside autoimmune diseases like rheumatoid arthritis and myasthenia gravis. RPI-MN: Under investigation for viral diseases, including human immunodeficiency virus (HIV/AIDS) and herpes, as well as for general antiviral applications. RPI-78: Being developed for applications in pain and arthritis. RPI-70: Also in development for pain relief. Founded in 2000, the company is headquartered in Plantation, Florida.
Grünenthal is a global pharmaceutical company that researches, develops, and commercializes innovative treatments and medicines with a primary focus on pain management and related diseases. Operating as a science-based business, the company serves patients worldwide by delivering therapies for conditions such as chronic pain, rare diseases, and neurobiological indications.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company based in San Mateo and Redwood City, California, focused on developing and commercializing therapeutic products.
Get Scilex Holding Co's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Scilex Holding Co in Xcout Intel
- 23 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access